AstraZeneca shakes up exec team during Alexion takeover

June 4, 2021

AstraZeneca plans to shuffle key execs, using the $39 billion takeover of rare diseases powerhouse Alexion as an opportunity to freshen up it management team.

The drugmaker will move AstraZeneca CFO Marc Dunoyer to head the newly acquired rare diseases business at Alexion, replacing Ludwig Hantson as CEO on completion of the agreed deal. Dunoyer will also serve as AstraZeneca's chief strategy officer.

The proposed switch will allow Aradhana Sarin, currently the executive vice president and CFO of Alexion, to move in the opposite direction and become AstraZeneca's CFO. The switch will happen starting either August 1 or the date of the acquisition's close.

India-born Sarin will become the first woman to take up the CFO role at AstraZeneca on a permanent basis.

Read the press release